Magazine Article | June 1, 2021

Why The DTP Model Is A Win For Drug Manufacturers And Patients

Source: Life Science Leader

By Jay McHarg

Pre-COVID, typically DTP was only a distribution tactic for specialty medicines not generally sold in commercial pharmacies. But similar to telemedicine, once access was greatly diminished, alternatives started to emerge, including curbside pickup and in-town delivery.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader